Professor Simon Lewis, Lead Clinician for the Australian Parkinson’s Mission (APM001) clinical trial, presents the results of this landmark Phase II study investigating three repurposed medicines as potential disease-modifying treatments for Parkinson’s disease.
Conducted across eight Australian sites, the randomised, double-blind, placebo-controlled trial evaluated alogliptin, albuterol and nilvadipine in 168 people with moderate Parkinson’s disease over 60 weeks. While all three medications were found to be safe and well tolerated, the study did not demonstrate a significant clinical benefit in slowing disease progression or improving symptoms compared with placebo.
In this presentation, Professor Lewis explains the study design, the primary and secondary outcomes, and the implications of these findings for Parkinson’s research. He discusses why rigorously conducted clinical trials remain essential in the search for therapies that can modify the course of this progressive neurological condition and how results such as these help guide future research.
The APM001 trial forms part of the Australian Parkinson’s Mission, a seven-year national research program bringing together leading Australian and international partners to accelerate the development of precision medicine approaches and disease-modifying treatments for people living with Parkinson’s disease.
Volunteer for our research here: https://bit.ly/PDRC_EOI